Discovery and saturation analysis of cancer genes across 21 tumor types

Nature (Impact Factor: 41.46). 01/2014; 505(7484). DOI: 10.1038/nature12912
Source: PubMed


Although a few cancer genes are mutated in a high proportion of tumours of a given type (>20%), most are mutated at intermediate frequencies (2-20%). To explore the feasibility of creating a comprehensive catalogue of cancer genes, we analysed somatic point mutations in exome sequences from 4,742 human cancers and their matched normal-tissue samples across 21 cancer types. We found that large-scale genomic analysis can identify nearly all known cancer genes in these tumour types. Our analysis also identified 33 genes that were not previously known to be significantly mutated in cancer, including genes related to proliferation, apoptosis, genome stability, chromatin regulation, immune evasion, RNA processing and protein homeostasis. Down-sampling analysis indicates that larger sample sizes will reveal many more genes mutated at clinically important frequencies. We estimate that near-saturation may be achieved with 600-5,000 samples per tumour type, depending on background mutation frequency. The results may help to guide the next stage of cancer genomics.

  • Source
    • "Ewing sarcoma remains such a monster, a " genetically engineered monster " with the EWSR1-ETS gene fusion as the major driver of its nefarious activities, as Paul Meltzer pointed out while introducing the topic of " Spatial and temporal genetic and non-genetic diversity of Ewing sarcoma " (Table 1). From recent sequencing studies it has become clear that with the exception of the well-known EWSR1-ETS gene fusions, which drive a complex tumor specific transcriptional program, the Ewing sarcoma genome is relatively quiet56789. Franck Tirode provided an overview on the molecular heterogeneity of Ewing and Ewing-like tumors in a cohort of 130 sarcomas. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite multimodal treatment, long term outcome for patients with Ewing sarcoma is still poor. The second "European interdisciplinary Ewing sarcoma research summit" assembled a large group of scientific experts in the field to discuss their latest unpublished findings on the way to the identification of novel therapeutic targets and strategies. Ewing sarcoma is characterized by a quiet genome with presence of an EWSR1-ETS gene rearrangement as the only and defining genetic aberration. RNA-sequencing of recently described Ewing-like sarcomas with variant translocations identified them as biologically distinct diseases. Various presentations adressed mechanisms of EWS-ETS fusion protein activities with a focus on EWS-FLI1. Data were presented shedding light on the molecular underpinnings of genetic permissiveness to this disease uncovering interaction of EWS-FLI1 with recently discovered susceptibility loci. Epigenetic context as a consequence of the interaction between the oncoprotein, cell type, developmental stage, and tissue microenvironment emerged as dominant theme in the discussion of the molecular pathogenesis and inter- and intra-tumor heterogeneity of Ewing sarcoma, and the difficulty to generate animal models faithfully recapitulating the human disease. The problem of preclinical development of biologically targeted therapeutics was discussed and promising perspectives were offered from the study of novel in vitro models. Finally, it was concluded that in order to facilitate rapid pre-clinical and clinical development of novel therapies in Ewing sarcoma, the community needs a platform to maintain knowledge of unpublished results, systems and models used in drug testing and to continue the open dialogue initiated at the first two Ewing sarcoma summits.
    Full-text · Article · Jan 2016 · Oncotarget
  • Source
    • "Most interestingly, ELF3 a transcriptional regulator of TGFBR2 was mutated in 10.6% of the periampullary tumors with predominantly inactivating frameshift or nonsense mutations (Figure 3B). This mutation frequency is three times higher than in any other cancer (Table S3D) (Cerami et al., 2012;Gao et al., 2013;Lawrence et al., 2014) ( In agreement with our finding, ELF3 mutations were found in 9.5% of extrahepathic CAC in a recent study of 74 samples with four inactivating mutations out of seven (Nakamura et al., 2015). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The ampulla of Vater is a complex cellular environment from which adenocarcinomas arise to form a group of histopathologically heterogenous tumors. To evaluate the molecular features of these tumors, 98 ampullary adenocarcinomas were evaluated and compared to 44 distal bile duct and 18 duodenal adenocarcinomas. Genomic analyses revealed mutations in the WNT signaling pathway among half of the patients and in all three adenocarcinomas irrespective of their origin and histological morphology. These tumors were characterized by a high frequency of inactivating mutations of ELF3, a high rate of microsatellite instability, and common focal deletions and amplifications, suggesting common attributes in the molecular pathogenesis are at play in these tumors. The high frequency of WNT pathway activating mutation, coupled with small-molecule inhibitors of β-catenin in clinical trials, suggests future treatment decisions for these patients may be guided by genomic analysis.
    Full-text · Article · Jan 2016 · Cell Reports
  • Source
    • "Though no enrichment for any candidate ASD risk gene sets were observed in the set of up-regulated genes, cancer associated genes, defined by The Cancer Genome Atlas, were enriched in this group. Loss of CHD8 function has been observed in a broad range of tumor types and other chromatin regulators have been implicated in cancer development (Lawrence et al., 2014). This suggests CHD8 may have other important roles extending past development and may be a point of commonality between some cancers and ASD. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Autism Spectrum Disorder (ASD) is a common neurodevelopmental disorder with a strong but complex genetic component. Recent family based exome-sequencing strategies have identified recurrent de novo mutations at specific genes, providing strong evidence for ASD risk, but also highlighting the extreme genetic heterogeneity of the disorder. However, disruptions in these genes converge on key molecular pathways early in development. In particular, functional enrichment analyses have found that there is a bias toward genes involved in transcriptional regulation, such as chromatin modifiers. Here we review recent genetic, animal model, co-expression network, and functional genomics studies relating to the high confidence ASD risk gene, CHD8. CHD8, a chromatin remodeling factor, may serve as a "master regulator" of a common ASD etiology. Individuals with a CHD8 mutation show an ASD subtype that includes similar physical characteristics, such as macrocephaly and prolonged GI problems including recurrent constipation. Similarly, animal models of CHD8 disruption exhibit enlarged head circumference and reduced gut motility phenotypes. Systems biology approaches suggest CHD8 and other candidate ASD risk genes are enriched during mid-fetal development, which may represent a critical time window in ASD etiology. Transcription and CHD8 binding site profiles from cell and primary tissue models of early development indicate that CHD8 may also positively regulate other candidate ASD risk genes through both direct and indirect means. However, continued study is needed to elucidate the mechanism of regulation as well as identify which CHD8 targets are most relevant to ASD risk. Overall, these initial studies suggest the potential for common ASD etiologies and the development of personalized treatments in the future.
    Full-text · Article · Dec 2015 · Frontiers in Neuroscience
Show more